Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway.
SourceAnti-Cancer Drugs, 23, 2, (2012), pp. 149-54
01 februari 2012
Article / Letter to editor
Display more detailsDisplay less details
SubjectIGMD 5: Health aging / healthy living; NCEBP 14: Cardiovascular diseases; NCEBP 7: Effective primary care and public health ONCOL 2: Age-related aspects of cancer; NCMLS 2: Immune Regulation ONCOL 3: Translational research; ONCOL 2: Age-related aspects of cancer NCEBP 4: Quality of hospital and integrated care; ONCOL 3: Translational research
Weight loss, cachexia and sarcopenia are profound problems in the frail oncologic patients. With the development and increasing use of angiogenesis inhibitors in metastatic cancer patients, the question arises as to their influence on body weight and composition. Angiogenesis is not only important for the growth, development and metastatic potential of tumors but also for physiological processes in adipogenesis. A less known approach of angiogenesis inhibitors is their experimental use in obese models. This review focuses on the effects on the body weight and composition of angiogenesis inhibitors, especially of those targeting the vascular endothelial growth factor pathway.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.